Besins Healthcare to start production of progesterone in Russia

4 February 2019

Bangkok, Thailand-basedBesins Healthcare has officially announced the completion of construction of a new pharmaceutical factory in the Russian Yaroslavl region, according to the company, reports The Pharma Letter’s local correspondent.

The new plant, on which building initially started on 2016, will specialize on the production of micronized progesterone, which is a complete analogue of the female hormone progesterone and is widely used in the field of obstetrics and gynecology. It is currently on the list of essential drugs in Russia.

Olga Volkova, general director of Besins Healthcare Rus, a Russian subsidiary of the company, said Besins has not ruled out the possibility of expanding production capacities of the Yaroslavl plant in due course.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK